GeneDx posts 41% revenue growth, issues 2026 guidance

GeneDx Holdings Corp. (NASDAQ: WGS) reported preliminary 2025 financial results showing revenue of approximately $427 million, representing a 41% increase from the prior year, according to a company statement.

The genomic testing company expects fourth quarter 2025 revenues of $121 million, up 27% year-over-year. Exome and genome revenues reached approximately $360 million for the full year, marking a 54% increase, or 58% excluding a one-time 2024 benefit.

GeneDx processed 97,271 exome and genome tests in 2025, a 30.5% volume increase from 2024. The fourth quarter showed accelerated growth with 27,761 tests, up 34.3% year-over-year.

The company maintained adjusted gross margins of approximately 71% for both the full year and fourth quarter 2025. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $172 million as of December 31, 2025.

For 2026, GeneDx projects revenues between $540 million and $555 million, with exome and genome revenue growth of 33% to 35%. The company expects adjusted gross margin of at least 70% and positive adjusted net income for the year.

"We delivered on our commitment to drive more than 30% growth for the year with volume growth rates accelerating each quarter," said Kevin Feeley, CFO of GeneDx.

The preliminary results are unaudited and subject to adjustment as the company completes its 2025 year-end financial statements and audit. GeneDx plans to release final fourth quarter and full year 2025 results on February 23, 2026.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Citigroup set to join top banks in Anthropic IPO - Bloomberg
• GitLab releases version 19.3 with AI gateway and secrets tools